Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[New anticoagulants].

M Levi1, R J G Peters, J J Piek

  • 1Afd. Inwendige Geneeskunde/Vasculaire Geneeskunde, Academisch Medisch Centrum/Universiteit van Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam. m.m.levi@amc.uva.nl

Nederlands Tijdschrift Voor Geneeskunde
|May 29, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Longitudinal Study of Thrombosis and Bleeding Outcomes With Thromboprophylaxis in Pregnant Women at Intermediate and High Risk of VTE.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2023
Same author

Recommendations for the diagnosis and management of vaccine-induced immune thrombotic thrombocytopenia.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2021
Same author

Venous thromboembolism in cancer patients: a population-based cohort study.

Blood·2020
Same author

Thromboembolic and bleeding complications in patients with oesophageal cancer.

The British journal of surgery·2020
Same author

Corrigendum to "Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study" [Thromb. Res. vol. 185, January 2020, pages 13-19].

Thrombosis research·2020
Same author

Perioperative bridging of anticoagulation: towards a more reserved approach.

The Netherlands journal of medicine·2019

New platelet aggregation inhibitors and anticoagulants show higher efficacy than current options. These novel agents offer more convenient clinical use, though with a slightly increased bleeding risk.

Area of Science:

  • Pharmacology
  • Hematology
  • Cardiovascular Medicine

Context:

  • Numerous novel platelet aggregation inhibitors and anticoagulants are under clinical investigation.
  • These agents target recently identified key in vivo hemostatic pathways.
  • Current anticoagulants have limitations in efficacy and convenience.

Purpose:

  • To review and categorize newly developed antithrombotic agents.
  • To compare the efficacy and clinical utility of new agents versus existing ones.
  • To highlight advancements in targeting hemostatic pathways.

Summary:

  • New agents include thienopyridine derivatives (e.g., clopidogrel) and glycoprotein IIb/IIIa receptor antagonists (e.g., abciximab).
  • Novel anticoagulants encompass direct thrombin inhibitors (e.g., hirudine), factor Xa inhibitors (e.g., fondaparinux), and inhibitors of the tissue factor VIIa complex.

Related Experiment Videos

  • These advancements generally offer higher efficacy and improved convenience compared to established treatments, albeit with a potential modest increase in bleeding risk.

    • Impact:

    • These new antithrombotic drugs represent significant progress in cardiovascular and thrombotic disease management.
    • Enhanced efficacy and convenience could improve patient outcomes and adherence.
    • Further research is crucial to fully elucidate the risk-benefit profiles of these novel agents.